Amanda Linkous

Amanda Linkous

Auto-generated profile, based on publicly available information

Amanda Linkous

Department of Pharmacology, Vanderbilt University, Nashville, TN, United States

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Cell Reports
Verified
Journal Article
Open access
ALAmanda Linkous
Amanda Linkous
DBDemosthenes Balamatsias
Demosthenes Balamatsias
MSMatija Snuderl
Matija Snuderl
LELincoln Edwards
Lincoln Edwards
KMKen Miyaguchi
Ken Miyaguchi
HFHoward A. Fine
Howard A. Fine
The prognosis of patients with glioblastoma (GBM) remains dismal, with a median survival of approximately 15 months. Current preclinical GBM models are limited by the lack of a "normal" human microenvironment and the inability of many tumor cell lines to accurately reproduce GBM biology. To address these limitations, we have established a model system whereby we can retro-engineer patient-specific GBMs using patient-derived glioma stem cells (GSCs) and human embryonic stem cell (hESC)-derived cerebral organoids. Our cerebral organoid glioma (GLICO) model shows that GSCs home toward the human cerebral organoid and deeply invade and proliferate within the host tissue, forming tumors that closely phenocopy patient GBMs. Furthermore, cerebral organoid tumors form rapidly and are supported by an interconnected network of tumor microtubes that aids in the invasion of normal host tissue. Our GLICO model provides a system for modeling primary human GBM ex vivo and for high-throughput drug screening.

1 July 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
APAllison R. Pine
Allison R. Pine
SCStefano M. Cirigliano
Stefano M. Cirigliano
JNJames G. Nicholson
James G. Nicholson
YHYang Hu
Yang Hu
ALAmanda Linkous
Amanda Linkous
HFHoward A. Fine
Howard A. Fine
Glioblastoma (GBM), an incurable tumor, remains difficult to model and more importantly to treat due to its genetic/epigenetic heterogeneity and plasticity across cellular states. The ability of current tumor models to recapitulate the cellular states found in primary tumors remains unexplored. To address this issue, we compared single-cell RNA sequencing of tumor cells from 5 patients across four patient-specific glioblastoma stem cell (GSC)–derived model types, including glioma spheres, tumor organoids, glioblastoma cerebral organoids (GLICO), and patient-derived xenografts. We find that GSCs within the GLICO model are enriched for a neural progenitor–like cell subpopulation and recapitulate the cellular states and their plasticity found in the corresponding primary parental tumors. These data demonstrate how the contribution of a neuroanatomically accurate human microenvironment is critical and sufficient for recapitulating the cellular states found in human primary GBMs, a principle that may likely apply to other tumor models. Significance: It has been unclear how well different patient-derived GBM models are able to recreate the full heterogeneity of primary tumors. Here, we provide a complete transcriptomic characterization of the major model types. We show that the microenvironment is crucial for recapitulating GSC cellular states, highlighting the importance of tumor–host cell interactions. See related commentary by Luo and Weiss, p. 907. This article is highlighted in the In This Issue feature, p. 890

20 August 2010 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
ALAmanda G. Linkous
Amanda G. Linkous
EYEugenia M. Yazlovitskaya
Eugenia M. Yazlovitskaya
DHDennis E. Hallahan
Dennis E. Hallahan
Lung cancer and glioblastoma multiforme are highly angiogenic and, despite advances in treatment, remain resistant to therapy. Cytosolic phospholipase A2 (cPLA 2 ) activation contributes to treatment resistance through transduction of prosurvival signals. We investigated cPLA 2 as a novel molecular target for antiangiogenesis therapy. Glioblastoma (GL261) and Lewis lung carcinoma (LLC) heterotopic tumor models were used to study the effects of cPLA 2 expression on tumor growth and vascularity in C57/BL6 mice wild type for (cPLA 2 α +/+ ) or deficient in (cPLA 2 α −/− ) cPLA 2 α, the predominant isoform in endothelium (n = 6–7 mice per group). The effect of inhibiting cPLA 2 activity on GL261 and LLC tumor growth was studied in mice treated with the chemical cPLA 2 inhibitor 4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1 H -indol-3-yl]-ethoxy]benzoic acid (CDIBA). Endothelial cell proliferation and function were evaluated by Ki-67 immunofluorescence and migration assays in primary cultures of murine pulmonary microvascular endothelial cells (MPMEC) isolated from cPLA 2 α +/+ and cPLA 2 α −/− mice. Proliferation, invasive migration, and tubule formation were assayed in mouse vascular endothelial 3B-11 cells treated with CDIBA. Effects of lysophosphatidylcholine, arachidonic acid, and lysophosphatidic acid (lipid mediators of tumorigenesis and angiogenesis) on proliferation and migration were examined in 3B-11 cells and cPLA 2 α −/− MPMEC. All statistical tests were two-sided. GL261 tumor progression proceeded normally in cPLA 2 α +/+ mice, whereas no GL261 tumors formed in cPLA 2 α −/− mice. In the LLC tumor model, spontaneous tumor regression was observed in 50% of cPLA 2 α −/− mice. Immunohistochemical examination of the remaining tumors from cPLA 2 α −/− mice revealed attenuated vascularity ( P ≤ .001) compared with tumors from cPLA 2 α +/+ mice. Inhibition of cPLA 2 activity by CDIBA resulted in a delay in tumor growth (eg, LLC model: average number of days to reach tumor volume of 700 mm 3 , CDIBA vs vehicle: 16.8 vs 11.8, difference = 5, 95% confidence interval = 3.6 to 6.4, P = .04) and a decrease in tumor size (eg, GL261 model: mean volume on day 21, CDIBA vs vehicle: 40.1 vs 247.4 mm 3 , difference = 207.3 mm 3 , 95% confidence interval = 20.9 to 293.7 mm 3 , P = .021). cPLA 2 deficiency statistically significantly reduced MPMEC proliferation and invasive migration ( P = .002 and P = .004, respectively). Compared with untreated cells, cPLA 2 α −/− MPMEC treated with lysophosphatidylcholine and lysophosphatidic acid displayed increased cell proliferation ( P = .011) and invasive migration ( P < .001). In these mouse models of brain and lung cancer, cPLA 2 and lysophospholipids have key regulatory roles in tumor angiogenesis. cPLA 2 inhibition may be a novel effective antiangiogenic therapy.

14 July 2010 in Cellular Microbiology
Verified
Journal Article
Closed access
PDF file
ALAmanda Linkous
Amanda Linkous
EYEugenia M. Yazlovitskaya
Eugenia M. Yazlovitskaya
As efficient catalysts, enzymes help maintain a variety of biological and chemical transformations necessary for cellular metabolism and normal physiology. Unfortunately, pathogenic microbes can also exploit enzymatic reactions in an attempt to spread infection. Cytosolic phospholipase A2 (cPLA(2) ) is an enzyme that is responsible for the hydrolysis of membrane phospholipids such as phosphatidylcholine. Following activation, cPLA(2) cleaves phosphatidylcholine to yield free fatty acid and lysophosphatidylcholine. Both of these products and their downstream metabolites initiate a network of signalling cascades that influence cellular viability and inflammation. Recent observations have shown that viral and bacterial agents often target this intricate organization of signalling molecules. This review briefly discusses the role of cPLA(2) in the biological response to disease-causing pathogens and injury, the immunological process and tumour progression.

20 July 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSStephen M. Schleicher
Stephen M. Schleicher
DTDinesh K. Thotala
Dinesh K. Thotala
ALAmanda G. Linkous
Amanda G. Linkous
RHRong Hu
Rong Hu
KLKathleen M. Leahy
Kathleen M. Leahy
DHDennis E. Hallahan
Dennis E. Hallahan
Despite wide margins and high dose irradiation, unresectable malignant glioma (MG) is less responsive to radiation and is uniformly fatal. We previously found that cytosolic phospholipase A2 (cPLA2) is a molecular target for radiosensitizing cancer through the vascular endothelium. Autotaxin (ATX) and lysophosphatidic acid (LPA) receptors are downstream from cPLA2 and highly expressed in MG. Using the ATX and LPA receptor inhibitor, α-bromomethylene phosphonate LPA (BrP-LPA), we studied ATX and LPA receptors as potential molecular targets for the radiosensitization of tumor vasculature in MG. Treatment of Human Umbilical Endothelial cells (HUVEC) and mouse brain microvascular cells bEND.3 with 5 µmol/L BrP-LPA and 3 Gy irradiation showed decreased clonogenic survival, tubule formation, and migration. Exogenous addition of LPA showed radioprotection that was abrogated in the presence of BrP-LPA. In co-culture experiments using bEND.3 and mouse GL-261 glioma cells, treatment with BrP-LPA reduced Akt phosphorylation in both irradiated cell lines and decreased survival and migration of irradiated GL-261 cells. Using siRNA to knock down LPA receptors LPA1, LPA2 or LPA3 in HUVEC, we demonstrated that knockdown of LPA2 but neither LPA1 nor LPA3 led to increased viability and proliferation. However, knockdown of LPA1 and LPA3 but not LPA2 resulted in complete abrogation of tubule formation implying that LPA1 and LPA3 on endothelial cells are likely targets of BrP-LPA radiosensitizing effect. Using heterotopic tumor models of GL-261, mice treated with BrP-LPA and irradiation showed a tumor growth delay of 6.8 days compared to mice treated with irradiation alone indicating that inhibition of ATX and LPA receptors may significantly improve malignant glioma response to radiation therapy. These findings identify ATX and LPA receptors as molecular targets for the development of radiosensitizers for MG.

1 January 2013 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SBSandeep R. Bhave
Sandeep R. Bhave
DDDavid Y. A. Dadey
David Y. A. Dadey
RKRowan M. Karvas
Rowan M. Karvas
DFDaniel J. Ferraro
Daniel J. Ferraro
RKRama P. Kotipatruni
Rama P. Kotipatruni
DTDinesh Thotala
Dinesh Thotala
Purpose: Glioblastoma multiforme (GBM) is an aggressive primary brain tumor that is radio-resistant and recurs despite aggressive surgery, chemo, and radiotherapy. Autotaxin (ATX) is over expressed in various cancers including GBM and is implicated in tumor progression, invasion, and angiogenesis. Using the ATX specific inhibitor, PF-8380, we studied ATX as a potential target to enhance radiosensitivity in GBM. Methods and Materials: Mouse GL261 and Human U87-MG cells were used as GBM cell models. Clonogenic survival assays and tumor transwell invasion assays were performed using PF-8380 to evaluate role of ATX in survival and invasion. Radiation dependent activation of Akt was analyzed by immunoblotting. Tumor induced angiogenesis was studied using the dorsal skin fold model in GL261. Heterotopic mouse GL261 tumors were used to evaluate the efficacy of PF-8380 as a radiosensitizer. Results: Pre-treatment of GL261 and U87-MG cells with 1 μM PF-8380 followed by 4 Gy irradiation resulted in decreased clonogenic survival, decreased migration (33% in GL261; P = 0.002 and 17.9% in U87-MG; P = 0.012), decreased invasion (35.6% in GL261; P = 0.0037 and 31.8% in U87-MG; P = 0.002), and attenuated radiation-induced Akt phosphorylation. In the tumor window model, inhibition of ATX abrogated radiation induced tumor neovascularization (65%; P = 0.011). In a heterotopic mouse GL261 tumors untreated mice took 11.2 days to reach a tumor volume of 7000 mm3, however combination of PF-8380 (10 mg/kg) with irradiation (five fractions of 2 Gy) took more than 32 days to reach a tumor volume of 7000 mm3. Conclusion: Inhibition of ATX by PF-8380 led to decreased invasion and enhanced radiosensitization of GBM cells. Radiation-induced activation of Akt was abrogated by inhibition of ATX. Furthermore, inhibition of ATX led to diminished tumor vascularity and delayed tumor growth. These results suggest that inhibition of ATX may ameliorate GBM response to radiotherapy.